10:10 AM EDT, 07/22/2024 (MT Newswires) -- Atossa Therapeutics ( ATOS ) said Monday that it has completed patient enrollment for the 80-milligram pharmacokinetic run-in cohort of the phase 2 trial of (Z)-endoxifen and exemestane plus goserelin as a treatment for pre-menopausal women with breast cancer.

The company said the trial is specifically for grade 1 or 2 estrogen receptor positive/human epidermal growth factor receptor 2 negative breast cancer and the 80mg cohort comprises 12 pre-menopausal women. Atossa said it plans to proceed with the study's treatment cohort after determining the optimal dose of (Z)-endoxifen.

The phase 2 study is expected to enroll about 175 patients, with a primary objective of evaluating endocrine sensitive disease rate measured by Ki-67, a proliferation marker for disease-free survival, Atossa said.

Price: 1.32, Change: -0.02, Percent Change: -1.49